Abstract
Introduction

Cartilage forms the template on which bone is modelled, a process termed endochondral ossification. The mesenchymal cells from which chondrocytes derive are pluripotent and have the ability to differentiate into chondrocytes, osteoblasts, myocytes or adipocytes [1]. The molecular cues modulating the development of these mesenchymal cells ultimately determine their final identity and tissue characteristics. Chondrocyte differentiation is accompanied by unique changes in gene expression as cells progress through their life cycle in the growth plate. The Sox and Runx families of transcription factors control progression through the chondrocytic lineage, promoting cell condensation, proliferation and finally hypertrophy within a calcified, mineral matrix which the chondrocytes themselves produce [2]. The balance between proliferation and hypertrophy is finely tuned by the negative feedback loop of Indian hedgehog (Ihh) and parathyroid hormone-related peptide (PTHrP). Ihh, produced by pre-hypertrophic chondrocytes, induces PTHrP expression that prevents cells from initiating differentiation (reviewed in:
). Bone morphogenetic proteins and Wnts are also produced by hypertrophic chondrocytes and act in synergy with Ihh to induce osteogenesis of adjacent cells [5] . Various intracellular signalling pathways play a role in directing gene expression and regulate chondrocyte differentiation. These pathways include p38 MAPK [6] [7] [8] and GSK-3␤ [9] . [10, 11] [13] [14] [15] as well as chondrocytes [16] . PPAR␤/␦ is expressed ubiquitously [13, 17] and appears to be involved in fatty acid oxidation [18] . [19] [20] [21] [22] [23] [24] [25] . In addition to a dissimilar protein structure, these isoforms also display distinct expression patterns. PPAR␥2 is mainly expressed by adipose tissue, whereas PPAR␥1 displays ubiquitous expression [26, 27] . PPAR␥ has been best described for its role in adipogenesis and lipid storage [28] [29] [30] [31] ).
Similar to chondrocytes, the conversion of mesenchymal cells to adipocytes and osteoblasts requires molecular cues. The nuclear receptor peroxisome proliferator activated receptor (PPAR)␥2 is a critical regulator of adipogenesis (reviewed in
Unlike its relatives, PPAR␥ exists as two isoforms, PPAR␥1 and PPAR␥2. Both proteins are the product of the same gene, but arise from the use of different promoters. PPAR␥2 has an additional 28 (human) or 30 (mouse) amino acids at the NH2-terminal end
The expression of PPAR␥2 was first described in chondrocytes by Bordji et al. [32] who described that activation of PPAR␥ suppresses interleukin-1␤ effects on nitric oxide production and proteoglycan synthesis. More recently, Shao et al. [16] described expression of all three PPARs in growth plate chondrocytes. Although the function of PPAR␥ in chondrocytes remains largely unknown, it has been shown that activation of PPAR␥ inhibits T3-induced terminal differentiation and promotes apoptosis [33] . PPAR␥ activity has also been shown to suppress TGF-␤ induction of proteoglycan production [34] and to act as an anti-inflammatory agent in osteoarthritis [35] . These numerous functions have been suggested to be possible because of its wide range of ligands [36] .
Because chondrocytes are not readily presumed to be lipid storage or metabolizing cells, their lipid metabolism has been poorly investigated, though they are capable of lipid metabolism [37] . 
Chondrocyte micromass isolation and culture
Chondrocytes for micromass culture were isolated from hindlimb paddles of CD1 mouse embryos at 11.5 d.p.c as previously described [38] [39] . These experiments were repeated four independent times.
RNA isolation and real-time PCR
RNA isolation and real-time PCR was performed as previously described [38] . 
Immunohistochemical analysis
Three-micrometre metatarsal sections were deparaffinized in xylene, rehydrated through graded ethanols and processed for antigen localization as previously described with minor variations [40] . (Fig. 1H) and micromass (Fig. 1I) (Fig. 1H and I) . These data therefore show that p38 activity acts to suppress PPAR␥2 transcript expression levels in growth plate chondrocytes, whereas expression levels require GSK-3 activity.
Metatarsal bone growth is unaffected by the PPAR␥ agonist, troglitazone
PPAR␥ has been implicated in numerous functions including inhibition of T3-induced chondrocyte differentiation [33] . As (Fig. 3A) . In contrast, transcript levels of the hypertrophic marker collagen were reduced in response to PPAR␥ activation in monolayer cells (Fig. 3B) . Collagen X protein levels from metatarsals treated with troglitazone for 72 hrs mirrored the transcript level trends as determined from Western blot images (Fig. 3C) by spot densitometry (Fig. 3D) , although the effects on collagen X protein were relatively mild. These results suggest that 
c. embryos (A), 16.5 d.p.c. embryos (B), 17.5 d.p.c. embryos (C), metatarsals from 15.5 d.p.c embryos but maintained in culture for 72 hrs (D), as well as tibiae from freshly dissected 15.5 d.p.c. embryos (E) and 17.5 d.p.c. embryos (F). Cellular localization is indicated by the brown substrate. Magnification ϭ 100ϫ. (G) Total RNA was isolated from microdissected tibiae and analysed for PPAR␥2 transcript levels by real-time PCR. (H) Monolayer and (I) micromass chondrocytes were cultured as described in the presence and absence of 10 (M p38 inhibitor (PD169316) or GSK-3 inhibitor (SB216763) and harvested for PPAR␥2 transcript analysis by real-time PCR at the indicated times. Values are means ± S.E.M. of four independent chondrocyte cultures. The symbol '*' indicates significance of at least P Ͻ 0.04 compared to control cells at the indicated time-point.
PPAR␥ may inhibit chondrocyte maturation from the pre-hypertrophic to the hypertrophic stage. These results are in agreement with those of Shao et al. [41] and Wang et al. [42] who described inhibited T3-induced hypertrophic differentiation by PPAR␥ agonists.
PPAR␥ has been noted in numerous papers to promote adipocyte differentiation at the expense of osteogenesis [12, [43] [44] [45] . We have previously shown that chondrocyte cultures are capable of expressing osteoblast-associated genes, including Runx2, Osx and OCN [6] . As p38 inhibition has been shown to increase PPAR␥2 expression (Fig. 1E and F) , as well as Runx2, (Fig. 4) Runx2 and Osx expression compared to troglitazone treatment alone (Fig. 4) (Fig. 4) (Fig. 6A) (Fig. 6A) . Quantitative analyses showed that both size (Fig. 6B) and number (Fig. 6C) Fig. 6A and B) .
Osx and OCN [6], we next asked whether PPAR␥ activation affected expression of these genes. Using monolayer chondrocyte cultures we show that although increases in Runx2 and Osx transcript expression upon treatment with troglitazone for 8 days were not significant, OCN expression levels were significantly elevated in response to activation of PPAR␥ with troglitazone
. Effects of PPAR␥ on the three genes were abolished by GSK-3 inhibition, suggesting GSK-3 activity is required for appreciable expression of the osteoblast-associated genes under basal conditions, as well as PPAR␥-induced (troglitazone treated) osteoblast-associated gene expression in chondrocyte monolayer cultures.
PPAR␥ affects chondrocyte lipid metabolism through GSK-3␤ signalling
The number of lipid droplets in monolayer chondrocytes exposed to simultaneous treatment of p38 inhibition and troglitazone treatment resulted in fewer droplets per cell compared to PPAR␥ activation alone. However, when GSK-3 was inhibited with simultaneous PPAR␥ activation, the number of lipid droplets per cell was reduced further to levels similar to DMSO treated cultures. Taken together, these data suggest that GSK-3 activity, and to a lesser extent p38 activity, is required for PPAR␥-dependent lipid accumulation in chondrocytes.
Lipid-associated genes in chondrocytes are subject to expression regulation by p38 and GSK-3 (Fig. 7A) . Lpl transcript levels also increased over time in monolayer (Fig. 7B) and micromass (Fig. 7C) cultures, again similar to PPAR␥. Investigating the effect of p38 and GSK-3 activity on Lpl expression by pharmacological inhibitors in both monolayer (Fig. 7B) and micromass (Fig. 7C) (Fig. 7D) . These trends mirror those of PPAR␥2 expression. Furthermore, activation of PPAR␥ in chondrocyte cultures leads to elevated fatty acid binding protein 4 (Fabp4) (Fig. 7E) and Lpl (Fig. 7F) 
Because our results showed that PPAR␥ activation controls lipid metabolism in chondrocytes, we next examined the expression of genes involved in this process. Lipoprotein lipase (Lpl) is a wellaccepted downstream target gene of PPAR␥ in lipid metabolism. To confirm that PPAR␥ is functional and affecting lipid metabolism in chondrocytes, we investigated chondrocyte Lpl expression by real-time PCR. The resting/proliferative chondrocyte zone of microdissected tibiae expressed lower transcript levels compared to the hypertrophic region, similarly to PPAR␥2
cells demonstrates significantly increased expression of Lpl with p38 inhibition, whereas GSK-3 inhibition results in significantly reduced expression by the end of the time course. These effects are dose dependent for GSK-3 inhibition
Discussion
The expression pattern of PPAR␥ was once thought to be restricted to adipocytes. However, PPAR␥ expression has now been shown in many types of cells including trophoblasts [46] , monocytes and macrophages [47] , cardiac myocytes [48] and colonic epithelial cells [49] . The expression of PPAR␥ was first described in chondrocytes by Bordji et al. in 2000 [32] . The role of PPAR␥, PPAR␥ and PPAR␥ receptors in lipid metabolism, regulation of adipocyte proliferation and differentiation, as well as insulin sensitivity, is well accepted [50] . PPAR␥ is the target of the antidiabetic drugs thiazolinediones (TZDs) and has thus received a great deal of additional investigation, allowing the identification of additional functions including anti-inflammatory actions and regulation of differentiation and apoptosis [47, 51] [58, 59] .
Although 
